15,740 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Capstone Capital Management Ltd

Capstone Capital Management Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 15,740 shares of the biotechnology company’s stock, valued at approximately $987,000. Arrowhead Pharmaceuticals accounts for 1.0% of Capstone Capital Management Ltd’s investment portfolio, making the stock its 28th largest holding.

Several other large investors have also recently bought and sold shares of ARWR. Arrowstreet Capital Limited Partnership increased its position in shares of Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after buying an additional 2,017,489 shares in the last quarter. Norges Bank bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $113,159,000. Fred Alger Management LLC grew its stake in Arrowhead Pharmaceuticals by 497.4% in the fourth quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company’s stock valued at $121,693,000 after acquiring an additional 1,526,164 shares during the period. Deerfield Management Company L.P. acquired a new position in Arrowhead Pharmaceuticals in the third quarter valued at about $34,249,000. Finally, Vestal Point Capital LP bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $59,751,000. Institutional investors own 62.61% of the company’s stock.

Analyst Ratings Changes

ARWR has been the topic of a number of research analyst reports. Morgan Stanley raised Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 1st. Chardan Capital reissued a “buy” rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, June 30th. Royal Bank Of Canada raised their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Friday, May 1st. They issued an “overweight” rating and a $88.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.27.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director owned 52,012 shares of the company’s stock, valued at $3,998,682.56. This represents a 5.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at $11,623,271.75. This represents a 7.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 26,065 shares of company stock valued at $1,912,662. 3.60% of the stock is owned by insiders.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $85.74 on Thursday. The business’s 50-day moving average price is $77.52 and its two-hundred day moving average price is $69.23. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $14.30 and a 1 year high of $87.83. The company has a market capitalization of $12.08 billion, a price-to-earnings ratio of -39.88 and a beta of 1.26. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. The company had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The company’s quarterly revenue was down 86.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.75 earnings per share. Equities analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.